Gerald Heulitt, MD
Urology · North Little Rock, ARNPI 1366739971
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,713 of the $9,336 with a category attached, or 71.9%. It is spread thinly across 38 manufacturers, the largest accounting for just 14.9%. Reporting peaked in 2023 at $4,596 and has fallen 76.6% since, to $1,076 in 2025.
Across 209 payments — averaging $44.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Palette Life Sciences, Inc.$1K
- Myriad Genetic Laboratories, Inc.$967
- Johnson & Johnson$828
- Dendreon Pharmaceuticals LLC$757
- Astellas Pharma US Inc$549
- plus $3K from 32 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$500
What the payments were for
- Consulting fees$1,39515%
- Travel & lodging$98811%
- Food & beverage$6,71372%
- Education$2403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $1,395 |
| Palette Life Sciences, Inc. | 5 | $1,352 |
| Myriad Genetic Laboratories, Inc. | 12 | $967 |
| Johnson & Johnson | 25 | $828 |
| Dendreon Pharmaceuticals LLC | 16 | $757 |
| Astellas Pharma US Inc | 23 | $549 |
| Novartis | 21 | $399 |
| Myovant Sciences Inc. | 10 | $362 |
| Sumitomo Pharma America, Inc. | 14 | $360 |
| Pfizer | 15 | $339 |
| Teleflex LLC | 6 | $324 |
| Procept Biorobotics Corporation | 6 | $264 |
| AbbVie(2 entities) | 10 | $167 |
| Merck | 5 | $156 |
| Terumo Medical Corporation | 1 | $140 |
| Intuitive Surgical | 3 | $136 |
| Olympus America Inc. | 1 | $99 |
| Verity Pharmaceuticals Inc. | 4 | $98 |
| Urogen Pharma, Inc. | 3 | $88 |
| Bayer | 3 | $57 |
| Photocure Inc | 2 | $54 |
| Blue Earth Diagnostics | 2 | $54 |
| Endo USA, Inc. | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 1 | $36 |
| Boston Scientific | 1 | $36 |
| Rochester Medical Corporation | 2 | $34 |
| Urovant Sciences Inc | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Tolmar, Inc. | 1 | $28 |
| Antares Pharma, Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Cook Medical LLC | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Medtronic | 1 | $14 |
| Tempus AI, Inc | 1 | $14 |
| Axonics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$466
- PROVENGE$399
- ORGOVYX$360
- Erleada$320
- ANGIO-SEAL$140
- Azur CX Detachable$140
- UroLift$132
- XTANDI$113
- BRAC CDx$111
- Barrigel$110
- Da Vinci Surgical System$107
How this compares
$9,336 in reported general payments places this provider in the 60th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 65 | $938,256 |
| XtandiEnzalutamide | 32 | $451,990 |
| OrgovyxRelugolix | 22 | $54,464 |
| MyrbetriqMirabegron | 31 | $32,986 |
| EliquisApixaban | 11 | $6,474 |
| Tamsulosin Hcl | 443 | $5,293 |
| Oxybutynin Chloride ErOxybutynin Chloride | 138 | $1,970 |
| Finasteride | 177 | $1,667 |
| Megestrol Acetate | 49 | $901 |
| Solifenacin Succinate | 21 | $340 |
| Oxycodone Hcl | 147 | $241 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 24 | $138 |
| Prednisone | 13 | $120 |
| Ciprofloxacin Hcl | 64 | $107 |
| Alendronate Sodium | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $828 | $938,25665 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $549 | $484,97663 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $360 | $54,46422 claims |
| PfizerEliquis | $339 | $6,47411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 urology providers in Arkansas.
Other urology in North Little Rock
- Ronald KuhnNorth Little Rock$138K
- Edwin DiazNorth Little Rock$125K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
- David JacksPine Bluff$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.